DeltaRex-G (retroviral expression vectors bearing inhibitory genes) / GenVivo  >>  Phase 2
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
DeltaRex-G (retroviral expression vectors bearing inhibitory genes) / GenVivo
NCT00572130: Phase II Study of Intravenous Rexin-G in Osteosarcoma

Completed
2
22
US
Rexin-G Dose 1, Rexin-G Dose 2
Epeius Biotechnologies
Osteosarcoma
07/10
06/11
NCT00504998: Safety/Efficacy Study of Rexin-G to Treat Pancreatic Cancer

Completed
1/2
20
US
Rexin-G
Epeius Biotechnologies
Pancreatic Cancer
07/10
06/11
NCT00505271: Safety and Efficacy Study Using Rexin-G for Breast Cancer

Completed
1/2
20
US
Rexin-G
Epeius Biotechnologies
Breast Cancer
07/10
06/11
NCT00505713: Safety and Efficacy Study Using Rexin-G for Sarcoma

Completed
1/2
36
US
Rexin-G
Epeius Biotechnologies
Sarcoma
07/10
06/11
NCT04378244: CORONA: A Study Using DeltaRex-G Gene Therapy for Symptomatic COVID-19

Withdrawn
1/2
18
NA
DeltaRex-G, DeltaRex-G Retroviral Vector Encoding a Cyclin G1 Inhibitor
Aveni Foundation
COVID-19, Cytokine Storm, Acute Respiratory Distress Syndrome
12/23
07/24

Download Options